Company: CERO
Filing Date: 2025-02-13
Form Type: 424B3
Source: 0001213900-25-013493
Chunk: 6

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-13
Form: 424B3
Chunk 6
---
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On February 12, 2025, CERo Therapeutics Holdings,
Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company
has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”)
and has applied and been moved to the Nasdaq Capital Market, as required by the panel convened by Nasdaq (the “Nasdaq Panel”).

Regaining compliance with the Bid Price Requirement
is one of the conditions set forth by the Nasdaq Panel in its previously disclosed decision granting the Company’s request for an
extension (the “Extension”) to regain compliance with certain Nasdaq continued listing requirements until April 22, 2025.
The Company continues to make progress towards satisfaction of the other conditions.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Date: February 12, 2025 | CERO THERAPEUTICS HOLDINGS, INC. |                         |
|:------------------------|:---------------------------------|:------------------------|
|                         | By:                              | /s/ Chris Ehrlich       |
|                         | Name:                            | Chris Ehrlich           |
|                         | Title:                           | Chief Executive Officer |

<div align='center'>2</div>